ArticleInternational journal of hematology2014
Bronchiolitis obliterans with allogeneic hematopoietic cell transplantation: a 10-year experience of the Okayama BMT Group.
Article in International journal of hematology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Risk factors for bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation: a systematic review and meta-analysis.BMC pulmonary medicine · 2025Pooled it
- [Chinese expert consensus on the diagnosis and treatment of pulmonary chronic graft-versus-host disease (2026)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Article
- Clinical risk factors and prognostic model for patients with bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation.Bone marrow transplantation · 2024Article
- [Chinese expert consensus on the management of long-term complications after hematopoietic stem cell transplantation (2023)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2023Article
- Clinical characteristics of late-onset interstitial pneumonia after allogeneic hematopoietic stem cell transplantation.International journal of hematology · 2023Article
- Sleep-related breathing disorder in non-infectious pulmonary complications after pediatric allogeneic stem cell transplantation.Pediatric research · 2023Review
- [Chinese consensus on diagnosis and treatment of bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation (2022)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2022Article
- Detection of pulse rate elevation by Apple Watch in a patient with bronchiolitis obliterans syndrome after allogeneic stem cell transplantation.Annals of hematology · 2022Article
- Prevention of non-infectious pulmonary complications after intra-bone marrow stem cell transplantation in mice.PloS one · 2022Article
- Characterization of localized macrophages in bronchiolitis obliterans after allogeneic hematopoietic cell transplantation.International journal of hematology · 2021Article
- Efficacy and safety of high-dose budesonide/formoterol in patients with bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplant.Journal of thoracic disease · 2020Article
- [Clinical analysis of bronchiolitis obliterans syndrome after haplo- hematopoietic stem cell transplantation].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bronchiolitis obliterans (BO) is a devastating complication of allogeneic hematopoietic stem cell transplantation (HSCT). We retrospectively studied 465 patients who underwent HSCT in the Okayama BMT Group between 2000 and 2009, and describe the detailed clinical features of 13 patients with BO. The 5-year cumulative incidence of BO was 3.43 %. The median time from transplantation to onset of BO was 15 months. In seven of the 13 patients, the primary symptom was only cough, indicating that cough was an important initial symptom for early diagnosis. The median duration from the onset of BO to the requirement of O2 supplementation was 13 months and the main cause of death was respiratory failure. History of chronic graft-versus-host disease was a significant risk factor. Furthermore, female recipients were at greater risk of BO than male recipients; however, no other previously reported risk factors were detected. It is currently difficult to prevent BO on the basis of the reported risk factors. A novel strategy for the early diagnosis and treatment of BO is required.
Indexed as
Identifiers
24634108What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.